Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3748/wjg.v19.i44.7955 http://scihub22266oqcxt.onion/10.3748/wjg.v19.i44.7955 24307789!3848143!24307789     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24307789&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       World+J+Gastroenterol 2013 ; 19 (44): 7955-71 Nephropedia Template TP {{tp|p=24307789|t=2013. Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives |pdf=|usr=}}{{24307789}} gab.com Text Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives JO: World J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=24307789 #FOAvip Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer death in both men and women in the United States, with about 142820 new cases and 50830 deaths expected in 2013. Metastatic disease (mCRC) remains a challenge for oncologists worldwide due to its potential comorbidities. Recently, chemotherapy regimens containing 5-fluorouracil, leucovorin, oxaliplatin and irinotecan combinations are a standard of care in the metastatic disease. Currently, biological therapies involving vascular endothelial growth factor and epidermal growth factor receptor pathways, such as bevacizumab and cetuximab, have emerged as good option for improving mCRC patient survival. Now, aflibercept plus standard chemotherapy has also been approved in second line regimen for mCRC patients. Our review will discuss novel biological drugs and their indications for mCRC patients and will bring future perspectives in this regard. Twit Text FOAVip Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives ????World J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=24307789 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24307789 #FOAvip English Wikipedia <ref>{{Cite pmid|24307789}}</ref> Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives #MMPMID24307789 Marques I; Araujo A; de Mello RA World J Gastroenterol 2013[Nov]; 19 (44): 7955-71 PMID24307789show ga Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer death in both men and women in the United States, with about 142820 new cases and 50830 deaths expected in 2013. Metastatic disease (mCRC) remains a challenge for oncologists worldwide due to its potential comorbidities. Recently, chemotherapy regimens containing 5-fluorouracil, leucovorin, oxaliplatin and irinotecan combinations are a standard of care in the metastatic disease. Currently, biological therapies involving vascular endothelial growth factor and epidermal growth factor receptor pathways, such as bevacizumab and cetuximab, have emerged as good option for improving mCRC patient survival. Now, aflibercept plus standard chemotherapy has also been approved in second line regimen for mCRC patients. Our review will discuss novel biological drugs and their indications for mCRC patients and will bring future perspectives in this regard. |*Neovascularization, Pathologic[MESH] |Angiogenesis Inhibitors/*therapeutic use[MESH] |Animals[MESH] |Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH] |Colorectal Neoplasms/*drug therapy/*secondary[MESH] |Drug Design[MESH] |Humans[MESH] |Molecular Targeted Therapy[MESH] |Signal Transduction/drug effects[MESH]Anti-angiogenic therapies for metastatic colorectal cancer: current an(epmc).pdf DeepDyve Pubget Overpricing